3-[4-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-N-[1-[[(3S,12R,15Z,18R,21S,24S,25R)-3-(4-aminobutyl)-12-(3-amino-3-oxopropyl)-15-ethylidene-21-[(1S)-1-hydroxyethyl]-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxo-6-[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2-hydroxyhexadecanamide
| Internal ID | aa1304ef-fd73-4d7c-ba90-fe5052e15294 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides > Cyclic glycodepsipeptides |
| IUPAC Name | 3-[4-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-N-[1-[[(3S,12R,15Z,18R,21S,24S,25R)-3-(4-aminobutyl)-12-(3-amino-3-oxopropyl)-15-ethylidene-21-[(1S)-1-hydroxyethyl]-18-[(4-hydroxyphenyl)methyl]-7,25-dimethyl-2,5,8,11,14,17,20,23-octaoxo-6-[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethyl]-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-24-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2-hydroxyhexadecanamide |
| SMILES (Canonical) | CCCCCCCCCCCCCC(C(C(=O)NC(C(C)O)C(=O)NC1C(OC(=O)C(NC(=O)C(N(C(=O)CNC(=O)C(NC(=O)C(=CC)NC(=O)C(NC(=O)C(NC1=O)C(C)O)CC2=CC=C(C=C2)O)CCC(=O)N)C)C(C)OC3C(C(C(C(O3)CO)O)O)O)CCCCN)C)O)OC4C(C(C(CO4)O)OC5C(C(C(C(O5)CO)O)O)NC(=O)C)O |
| SMILES (Isomeric) | CCCCCCCCCCCCCC(C(C(=O)NC(C(C)O)C(=O)N[C@H]1[C@H](OC(=O)[C@@H](NC(=O)C(N(C(=O)CNC(=O)[C@H](NC(=O)/C(=C/C)/NC(=O)[C@H](NC(=O)[C@@H](NC1=O)[C@H](C)O)CC2=CC=C(C=C2)O)CCC(=O)N)C)C(C)OC3C(C(C(C(O3)CO)O)O)O)CCCCN)C)O)OC4C(C(C(CO4)O)OC5C(C(C(C(O5)CO)O)O)NC(=O)C)O |
| InChI | InChI=1S/C78H128N12O32/c1-9-11-12-13-14-15-16-17-18-19-20-24-49(119-77-65(106)66(48(97)36-116-77)122-76-57(82-41(7)95)62(103)59(100)50(34-91)120-76)61(102)74(114)88-55(38(4)94)71(111)89-56-39(5)117-75(115)46(23-21-22-31-79)85-73(113)58(40(6)118-78-64(105)63(104)60(101)51(35-92)121-78)90(8)53(99)33-81-67(107)45(29-30-52(80)98)84-68(108)44(10-2)83-69(109)47(32-42-25-27-43(96)28-26-42)86-70(110)54(37(3)93)87-72(56)112/h10,25-28,37-40,45-51,54-66,76-78,91-94,96-97,100-106H,9,11-24,29-36,79H2,1-8H3,(H2,80,98)(H,81,107)(H,82,95)(H,83,109)(H,84,108)(H,85,113)(H,86,110)(H,87,112)(H,88,114)(H,89,111)/b44-10-/t37-,38?,39+,40?,45+,46-,47+,48?,49?,50?,51?,54-,55?,56-,57?,58?,59?,60?,61?,62?,63?,64?,65?,66?,76?,77?,78?/m0/s1 |
| InChI Key | CHQQTUZEDAZDBH-UKQIGXNFSA-N |
| Popularity | 1 reference in papers |
| Molecular Formula | C78H128N12O32 |
| Molecular Weight | 1745.90 g/mol |
| Exact Mass | 1744.8757600 g/mol |
| Topological Polar Surface Area (TPSA) | 696.00 Ų |
| XlogP | -2.30 |
| Atomic LogP (AlogP) | -8.03 |
| H-Bond Acceptor | 33 |
| H-Bond Donor | 24 |
| Rotatable Bonds | 38 |
| DTXSID501046985 |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.7416 | 74.16% |
| Caco-2 | - | 0.8580 | 85.80% |
| Blood Brain Barrier | - | 0.9500 | 95.00% |
| Human oral bioavailability | - | 0.7286 | 72.86% |
| Subcellular localzation | Mitochondria | 0.4243 | 42.43% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.7916 | 79.16% |
| OATP1B3 inhibitior | + | 0.9189 | 91.89% |
| MATE1 inhibitior | - | 0.9400 | 94.00% |
| OCT2 inhibitior | - | 0.9500 | 95.00% |
| BSEP inhibitior | + | 0.9552 | 95.52% |
| P-glycoprotein inhibitior | + | 0.7417 | 74.17% |
| P-glycoprotein substrate | + | 0.8780 | 87.80% |
| CYP3A4 substrate | + | 0.7623 | 76.23% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8533 | 85.33% |
| CYP3A4 inhibition | + | 0.5066 | 50.66% |
| CYP2C9 inhibition | - | 0.8211 | 82.11% |
| CYP2C19 inhibition | - | 0.9061 | 90.61% |
| CYP2D6 inhibition | - | 0.8200 | 82.00% |
| CYP1A2 inhibition | - | 0.8897 | 88.97% |
| CYP2C8 inhibition | + | 0.8520 | 85.20% |
| CYP inhibitory promiscuity | - | 0.9493 | 94.93% |
| UGT catelyzed | - | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 0.9200 | 92.00% |
| Carcinogenicity (trinary) | Non-required | 0.5685 | 56.85% |
| Eye corrosion | - | 0.9859 | 98.59% |
| Eye irritation | - | 0.8953 | 89.53% |
| Skin irritation | - | 0.7614 | 76.14% |
| Skin corrosion | - | 0.9280 | 92.80% |
| Ames mutagenesis | - | 0.6378 | 63.78% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7284 | 72.84% |
| Micronuclear | + | 0.8900 | 89.00% |
| Hepatotoxicity | - | 0.6783 | 67.83% |
| skin sensitisation | - | 0.8693 | 86.93% |
| Respiratory toxicity | + | 0.7222 | 72.22% |
| Reproductive toxicity | + | 0.9111 | 91.11% |
| Mitochondrial toxicity | + | 0.9000 | 90.00% |
| Nephrotoxicity | - | 0.6826 | 68.26% |
| Acute Oral Toxicity (c) | III | 0.6485 | 64.85% |
| Estrogen receptor binding | - | 0.5263 | 52.63% |
| Androgen receptor binding | + | 0.7520 | 75.20% |
| Thyroid receptor binding | + | 0.7968 | 79.68% |
| Glucocorticoid receptor binding | + | 0.8450 | 84.50% |
| Aromatase binding | + | 0.8100 | 81.00% |
| PPAR gamma | + | 0.7818 | 78.18% |
| Honey bee toxicity | - | 0.6028 | 60.28% |
| Biodegradation | - | 0.8000 | 80.00% |
| Crustacea aquatic toxicity | + | 0.5848 | 58.48% |
| Fish aquatic toxicity | + | 0.8247 | 82.47% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 99.98% | 83.82% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.81% | 91.11% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.80% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.65% | 96.09% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 99.00% | 93.10% |
| CHEMBL3837 | P07711 | Cathepsin L | 98.97% | 96.61% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 98.76% | 94.45% |
| CHEMBL3038469 | P24941 | CDK2/Cyclin A | 98.33% | 91.38% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 97.41% | 99.17% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 96.52% | 90.08% |
| CHEMBL2345 | P51812 | Ribosomal protein S6 kinase alpha 3 | 95.85% | 95.64% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 95.41% | 98.59% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 95.32% | 92.86% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 94.68% | 97.25% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 94.48% | 100.00% |
| CHEMBL2563 | Q9UQL6 | Histone deacetylase 5 | 94.05% | 89.67% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 93.95% | 95.89% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 93.87% | 100.00% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 93.56% | 94.66% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 93.36% | 96.90% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 92.61% | 91.03% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 92.50% | 93.56% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 92.31% | 95.56% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 92.01% | 97.79% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 91.94% | 85.00% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 91.59% | 89.00% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 91.13% | 95.83% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 90.61% | 98.05% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 90.61% | 95.50% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 90.00% | 82.38% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 89.92% | 95.89% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 89.48% | 97.09% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 89.41% | 97.14% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 89.24% | 90.71% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 89.07% | 95.93% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 89.01% | 97.29% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 88.26% | 100.00% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 87.88% | 91.24% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 87.62% | 94.33% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 87.51% | 93.00% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 86.65% | 86.33% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 86.54% | 95.00% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 86.14% | 97.64% |
| CHEMBL215 | P09917 | Arachidonate 5-lipoxygenase | 86.01% | 92.68% |
| CHEMBL3091268 | Q92753 | Nuclear receptor ROR-beta | 85.61% | 95.50% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 85.10% | 94.75% |
| CHEMBL5555 | O00767 | Acyl-CoA desaturase | 84.76% | 97.50% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 84.45% | 88.56% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 84.16% | 85.14% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 84.01% | 93.18% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 83.95% | 92.32% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 83.53% | 89.50% |
| CHEMBL335 | P18031 | Protein-tyrosine phosphatase 1B | 83.34% | 95.17% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 83.15% | 98.03% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 82.63% | 92.88% |
| CHEMBL1255126 | O15151 | Protein Mdm4 | 81.95% | 90.20% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 81.69% | 94.73% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 80.94% | 88.42% |
| CHEMBL4071 | P08311 | Cathepsin G | 80.92% | 94.64% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 80.70% | 96.00% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 163107865 |
| LOTUS | LTS0087089 |
| wikiData | Q105102577 |